Dr Andrew Davies (University of Southampton, Southampton, UK) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses a phase II/III study comparing the efficacy and safety of lenalidomide versus investigator’s choice in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Studies continue to support the clinical importance of molecularly distinct subtypes of DLBCL.
ASH 2014: Phase II/III study of lenalidomide in relapsed/refractory diffuse large B-cell lymphoma
17th February 2015
Oncology
